- Home
- RMBI vs ACET Comparison
RMBI vs ACET Comparison
Compare RMBI & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- ACET
- Stock Information
- Founded
- RMBI 1887
- ACET 1947
- Country
- RMBI United States
- ACET United States
- Employees
- RMBI N/A
- ACET N/A
- Industry
- RMBI Major Banks
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- RMBI Finance
- ACET Health Care
- Exchange
- RMBI Nasdaq
- ACET Nasdaq
- Market Cap
- RMBI 127.9M
- ACET 124.1M
- IPO Year
- RMBI 2019
- ACET N/A
- Fundamental
- Price
- RMBI $12.79
- ACET $1.50
- Analyst Decision
- RMBI
- ACET Strong Buy
- Analyst Count
- RMBI 0
- ACET 4
- Target Price
- RMBI N/A
- ACET $15.25
- AVG Volume (30 Days)
- RMBI 7.6K
- ACET 440.0K
- Earning Date
- RMBI 10-18-2024
- ACET 08-13-2024
- Dividend Yield
- RMBI 4.40%
- ACET N/A
- EPS Growth
- RMBI N/A
- ACET N/A
- EPS
- RMBI 0.81
- ACET N/A
- Revenue
- RMBI $41,636,699.00
- ACET N/A
- Revenue This Year
- RMBI N/A
- ACET N/A
- Revenue Next Year
- RMBI N/A
- ACET N/A
- P/E Ratio
- RMBI $15.77
- ACET N/A
- Revenue Growth
- RMBI N/A
- ACET N/A
- 52 Week Low
- RMBI $9.44
- ACET $1.05
- 52 Week High
- RMBI $13.00
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- RMBI 61.17
- ACET 52.75
- Support Level
- RMBI $11.40
- ACET $1.33
- Resistance Level
- RMBI $12.80
- ACET $1.63
- Average True Range (ATR)
- RMBI 0.37
- ACET 0.11
- MACD
- RMBI 0.00
- ACET -0.00
- Stochastic Oscillator
- RMBI 95.71
- ACET 53.33
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.